Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit
New capabilities connect AI agents, scientific literature, and validated computational engines to accelerate model-informed drug development
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit.
The initiative expands the companies’ collaboration announced in May 2026, extending their work in GPU-accelerated simulation and AI-assisted modeling workflows into agentic drug development. Together, the companies are combining AI reasoning, scientific literature, validated computational engines, and scalable compute within a scientific workflow.
The announcement coincides with NVIDIA’s introduction of the BioNeMo Agent Toolkit at the BIO International Convention.
